8月7日，科美诊断今日收盘8.62元，上涨1.65%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到33.50倍，总市值34.58亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.79倍，行业中值37.86倍，科美诊断排 名第68位。 股东方面，截至2025年3月31日，科美诊断股东户数11024户，较上次增加1412户，户均持股市值35.28 万元，户均持股数量2.76万股。 科美诊断技术股份有限公司的主营业务是临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售。 公司的主要产品是LiCA系列产品、CC系列产品。报告期内，公司新获得境内外授权专利64项，其中境 内发明专利33项，境内实用新型专利20项，外观设计专利11项。展现出公司持续壮大的创新能力和技术 储备。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断33.5027.212.4234.58亿行业平均 54.7951.294.8011 ...

8月4日，科美诊断今日收盘8.76元，上涨3.18%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到34.04倍，创367天以来新低，总市值35.14亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，科美诊断排 名第68位。 股东方面，截至2025年3月31日，科美诊断股东户数11024户，较上次增加1412户，户均持股市值35.28 万元，户均持股数量2.76万股。 科美诊断技术股份有限公司的主营业务是临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售。 公司的主要产品是LiCA系列产品、CC系列产品。报告期内，公司新获得境内外授权专利64项，其中境 内发明专利33项，境内实用新型专利20项，外观设计专利11项。展现出公司持续壮大的创新能力和技术 储备。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断34.0427.652.4635.14亿行业平均 54.325 ...

Core Viewpoint - The company, Kemei Diagnostics, has shown a decline in revenue and net profit in the latest quarterly report, while its stock price has reached a new low in terms of rolling P/E ratio compared to the industry average [1][2]. Company Summary - Kemei Diagnostics closed at 7.73 yuan, up 2.11%, with a rolling P/E ratio of 30.04, marking a 77-day low and a total market capitalization of 3.101 billion yuan [1]. - The company operates in the clinical immunochemistry and chemiluminescence diagnostic testing sector, focusing on the research, production, and sales of diagnostic reagents and instruments [1]. - The main products include the LiCA series and CC series [1]. - In the reporting period, Kemei Diagnostics obtained 64 new domestic and international patents, including 33 domestic invention patents, 20 utility model patents, and 11 design patents, indicating strong innovation capability and technical reserves [1]. Financial Performance - For Q1 2025, Kemei Diagnostics reported revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]. Industry Summary - The average P/E ratio for the medical device industry is 52.34, with a median of 36.99, placing Kemei Diagnostics at the 64th position within the industry [2]. - The average P/B ratio for the industry is 4.60, while Kemei Diagnostics has a P/B ratio of 2.17 [2]. - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].